Clinical Trial Update: Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study [Phase 2]

View source ↗

Summary

Phase II trial evaluating tislelizumab in combination with eribulin for metastatic, heavily-treated triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN